MorphoSys AG ADR (MOR)

Get an in-depth profile of MorphoSys AG ADR, including a general overview of the company's business and key management, as well as employee data and location and contact information.

7.50 -0.01 (-0.20%)

01:29:59 Close USD Disclaimer

MorphoSys AG ADR Company Profile

Industry: Biotechnology & Medical Research
Sector: Healthcare
Employees: 544
Equity Type: ADR

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer’s diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Contact Information

Address: Planegg,82152 Germany
Phone: 49 89 89927 0
Fax: 49 89 89927 222
Web: https://www.morphosys.com

Top Executives

Name	Age	Since	Title
Marc Cluzel	66	2012	Independent Chairman of the Supervisory Board
Michael Brosnan	66	2018	Independent Member of the Supervisory Board
Krisja Vermeylen	59	2017	Independent Member of the Supervisory Board
George S. Golumbeski	64	2018	Independent Deputy Chairman of Supervisory Board
Sharon Curran	54	2019	Independent Member of Supervisory Board
Raymond W. Sweet	0	2016	Member of Scientific Advisory Board
Gunther R. Adolf	0	2016	Member of Scientific Advisory Board
Sergio A. Quezada	46	2016	Member of Scientific Advisory Board
Bruce D. Cheson	0	2016	Member of Scientific Advisory Board
Andrew Cheng	56	2022	Independent Member of Supervisory Board

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.